Racheal Ede

Enugu State

Freelance Health Writer at Freelance

Freelance Healthcare Content Marketing Writer | Content and Copywriter

Featured in: Favicon

forbes.com Favicon

yahoo.com

livescience.com Favicon

mother.ly

singlecare.com Favicon

msn.com

honehealth.com Favicon

medcentral.com Favicon

medscape.com Favicon

espanol.medscape.com

Articles

Combined Cardiovascular and Kidney Problems on the Rise

1 week ago | medcentral.com | Avery Hurt |Barbara Hazelden |Oladimeji Ewumi |Racheal Ede

Increasing numbers of adults are experiencing a progressive syndrome driven by the interaction of chronic kidney disease and cardiovascular disease, obesity, and other metabolic factors, based on data from a new review presented at the National Kidney Foundation Spring Clinical Meeting in Boston. What is Cardiovascular-Kidney-Metabolic Syndrome?
Altas tasas globales de depresión y ansiedad comórbidas en el dolor crónico

2 weeks ago | espanol.medscape.com | Racheal Ede

close ¿Está seguro que quiere cerrar su sesión?
Vitiligo Comorbidities and Confounding Factors Examined

4 weeks ago | medcentral.com | Lauren Hunter |Racheal Ede

A correlation between demographic and socioeconomic factors and the incidence of comorbid depression, anxiety, or hypothyroidism in individuals with vitiligo was demonstrated in recent research conducted by a team at Baylor College of Medicine. The study was presented at the Skin of Color Society’s Scientific Symposium in Orlando, FL, where it won third place for abstracts advancing skin of color dermatology.
Menopause Impacts Common Dermatoses, and Dermatologists Need to Catch Up

1 month ago | medcentral.com | Heidi Splete |Racheal Ede

Menopause was associated with increased risk and severity of alopecia, mainly frontal fibrosing alopecia (FFA) and female pattern hair loss, according to a systematic review presented at the 2025 American Academy of Dermatology meeting in Orlando, FL. The study also documented how menopause impacts common dermatoses, including psoriasis, acne, rosacea, melasma, hidradenitis suppurativa, and eczema.
6 ways to save money on aripiprazole

1 month ago | singlecare.com | Racheal Ede |Karen Berger

Key takeaways Aripiprazole (generic Abilify) is approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia, bipolar I disorder, autism spectrum disorders, Tourette syndrome, and as an add-on treatment for depression. Aripiprazole may be covered by commercial, Medicare, or Medicaid plans, but coverage varies by plan.
Sleep Health Needs to Be Part of Psoriasis Care

1 month ago | medcentral.com | Heidi Splete |Racheal Ede |Nicole A. Negbenebor |Amy Paturel

Individuals with psoriasis experienced greater sleep disturbance, sleep impairment, insomnia severity, anxiety, and depression compared to healthy controls, according to results from a cross-sectional questionnaire-based study presented at the 2025 American Academy of Dermatology (AAD) annual meeting in Orlando, FL.
Adverse Event Trends in Psoriasis Management

2 months ago | medcentral.com | Racheal Ede

The interleukin-23 (IL-23) inhibitors guselkumab, tildrakizumab, and risankizumab and the IL-12/23 inhibitor ustekinumab used for psoriasis management were associated with increased risk of adverse events (AEs) including paradoxical reactions, infections, and malignancies, according to results of a global post-marketing study published in BMC Pharmacology and Toxicology.
Treatment Advances in IgA Nephropathy

Jan 9, 2025 | medcentral.com | Racheal Ede

Interest in IgA nephropathy (IgAN) therapeutics has exploded in recent years, mainly due to novel insights into its pathogenesis and the approval of proteinuria reduction as a clinical trial endpoint. Two medications for IgAN, budesonide and sparsentan, have been fully approved by the US Food and Drug Administration (FDA), while another, iptacopan, has received accelerated approval (more on these below). Many promising medications are in the pipeline as well.
FDA Clears Cologuard 2.0 for CRC

Oct 15, 2024 | medcentral.com | Racheal Ede

The US Food and Drug Administration (FDA) has given a nod to the next-generation Cologuard Plus screening test for individuals 45 years of age and older at average risk for colorectal cancer (CRC). This comes 10 years after the original Cologuard (Exact Sciences) was approved in August 2014. Compared to the earlier version, Cologuard Plus includes novel biomarkers, some designed to increase the test’s specificity while maintaining or improving sensitivity.
Is TRT Safe? What Are the Side Effects

Aug 20, 2024 | honehealth.com | Racheal Ede

It's impossible to foresee whether you'll encounter TRT side effects. Being aware of possible reactions can help you address them early if they occur.